Sugemalimab Plus Chemotherapy Shows Clinical Promise but Lacks Cost-Effectiveness in Advanced Gastric Cancer
核心洞察
The GEMSTONE-303 Phase III trial demonstrated that sugemalimab plus chemotherapy significantly improved overall survival to 15.6 months versus 12.6 months with chemotherapy alone in advanced gastric cancer patients with PD-L1 (搜索) CPS ≥5.
Cost-effectiveness analysis revealed incremental cost-effectiveness ratios of $80,573.50 per QALY for CPS ≥5 patients and $64,428.81 per QALY for CPS ≥10 patients, both exceeding China's willingness-to-pay threshold of $40,344.
A 40% price reduction could make sugemalimab cost-effective in the CPS ≥10 subgroup, with a 48% probability of being economically viable at the current threshold.
A comprehensive cost-effectiveness analysis of sugemalimab plus chemotherapy for advanced gastric cancer has revealed significant clinical benefits but economic challenges in the Chinese healthcare system, despite breakthrough survival improvements demonstrated in the pivotal GEMSTONE-303 Phase III trial.
Clinical Efficacy Drives Treatment Promise
The GEMSTONE-303 Phase III trial, a randomized, double-blind, placebo-controlled study conducted across 54 sites in China, enrolled 479 patients with previously untreated, unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 (搜索) combined positive scores (CPS) of 5 or higher. Treatment with sugemalimab plus CAPOX (搜索) chemotherapy significantly prolonged survival compared with chemotherapy alone, achieving median overall survival of 15.6 months versus 12.6 months, and median progression-free survival of 7.6 months versus 6.1 months.
These benefits were achieved with a manageable safety profile, making GEMSTONE-303 the first study to demonstrate a statistically significant survival advantage for an anti-PD-L1 (搜索) antibody combined with chemotherapy in this disease setting. The trial results were published in JAMA, establishing sugemalimab as a promising first-line treatment option for patients with PD-L1-positive advanced gastric cancer.
Economic Analysis Reveals Cost Barriers
Despite the clinical success, a subsequent cost-effectiveness analysis published in Scientific Reports revealed significant economic challenges. Using a partitioned survival model with a 10-year time horizon from the Chinese healthcare system perspective, researchers evaluated direct medical costs including drug acquisition, adverse event management, and supportive care.
In patients with PD-L1 (搜索) CPS ≥5, the total cost of sugemalimab plus chemotherapy reached $44,907.87 compared with $15,901.41 for chemotherapy alone. This produced an incremental gain of 0.36 quality-adjusted life years (QALYs) at an added cost of $29,006.46, resulting in an incremental cost-effectiveness ratio (ICER) of $80,573.50 per QALY.
For patients with higher PD-L1 (搜索) expression (CPS ≥10), the sugemalimab regimen cost $45,679.79 versus $14,753.96 for chemotherapy, with a 0.48 QALY gain and an ICER of $64,428.81 per QALY. Both values exceeded China's willingness-to-pay threshold of $40,344 per QALY, which represents three times the Chinese GDP per capita.
Sensitivity Analysis Identifies Key Economic Drivers
Comprehensive sensitivity analyses demonstrated that the ICER was most influenced by drug price and utility values for progression-free and progressive disease states. However, results remained above the cost-effectiveness threshold across all parameter variations tested within ±20% ranges.
Probabilistic sensitivity analysis confirmed a 0% probability of cost-effectiveness in the CPS ≥5 population and only 1.5% probability in the CPS ≥10 subgroup at current pricing. Notably, a 40% price reduction lowered the ICER in the CPS ≥10 group to $41,000.04 per QALY, raising the probability of cost-effectiveness to 48%.
Biomarker-Driven Approach Shows Promise
The analysis revealed that higher PD-L1 (搜索) expression levels correlated with improved cost-effectiveness ratios. The CPS ≥10 subgroup demonstrated the lowest ICER compared to the broader CPS ≥5 population, suggesting that biomarker-driven patient selection could optimize treatment value.
This finding underscores the potential for precision medicine approaches in gastric cancer treatment. The significance of baseline PD-L1 (搜索) expression in predicting treatment response to anti-PD-1 (搜索) and anti-PD-L1 therapies is widely recognized, and leveraging such biomarkers to tailor treatment regimens could enhance both clinical outcomes and cost-effectiveness.
Mechanism of Action and Clinical Context
Sugemalimab is a fully human monoclonal antibody developed by CStone Pharmaceuticals in collaboration with EQRx that targets programmed death-ligand 1 (PD-L1 (搜索)). By blocking PD-L1, sugemalimab prevents the protein from binding to PD-1 (搜索) receptors on T cells, restoring immune system activity against tumor cells.
Gastric cancer remains one of the most common and lethal cancers worldwide, with China carrying a significant share of the global burden. Standard chemotherapy provides limited benefit, with median survival rarely exceeding one year. The advent of immune checkpoint inhibitors has expanded treatment options, particularly for patients with PD-L1 (搜索)-positive tumors.
Treatment Protocol and Patient Population
In the GEMSTONE-303 trial, patients received sugemalimab intravenously at 1200 mg every 21 days or placebo, combined with CAPOX (搜索) therapy consisting of oral capecitabine at 1000 mg/m²/day twice daily for 14 days and intravenous oxaliplatin at 130 mg/m² on day 1, administered every 21 days. Treatment continued until disease progression or unacceptable toxicity.
The study focused on patients aged 18-75 with unresectable, locally advanced, or metastatic gastric adenocarcinoma, adequate tumor tissue for PD-L1 (搜索) assessment, and baseline PD-L1 CPS scores of 5 or higher. Subsequent anticancer therapy was administered to 129 patients (53.5%) in the sugemalimab group and 145 patients (60.9%) in the placebo group.
Policy Implications and Future Directions
While the analysis concluded that sugemalimab plus chemotherapy is not currently cost-effective in China compared with chemotherapy alone, researchers emphasized that cost-effectiveness analysis should not limit access to clinically effective treatments. The findings suggest that drug price reductions and biomarker-driven patient selection could improve economic viability.
The study authors recommended utilizing these cost-effectiveness findings to guide policy decisions and investigate strategies for enhancing the economic viability and accessibility of sugemalimab. The combination of clinical efficacy with targeted patient selection based on PD-L1 (搜索) expression levels represents a pathway toward optimizing both therapeutic outcomes and healthcare resource allocation in advanced gastric cancer treatment.